BRIDGEWATER, N.J., July 8, 2022 — Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and …
BRIDGEWATER, N.J., June 3, 2022 — Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious …
BRIDGEWATER, N.J., May 23, 2022 — Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious …
—Retrospective Cohort Study Shows Significant Reductions in All-Cause and Respiratory Disease-Related Hospitalizations in the 12 Months Following ARIKAYCE® (amikacin liposome inhalation suspension) Initiation in Real-World …
BRIDGEWATER, N.J., May 6, 2022 — Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and …
–ARIKAYCE® (amikacin liposome inhalation suspension) Achieves 32% Year Over Year Growth for the First Quarter of 2022 with Total Revenue of $53.1 Million— –Seven Clinical …
BRIDGEWATER, N.J., April 21, 2022 — Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and …
BRIDGEWATER, N.J., April 7, 2022 — Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and …
–Real-World Evidence Evaluating Reduction in Hospitalizations Following Initiation of use of ARIKAYCE® (amikacin liposome inhalation suspension) to be Presented in Poster Discussion Session– –Analysis of …
BRIDGEWATER, N.J., March 4, 2022 — Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious …